Few antimicrobials are available to treat ventilated associated pneumonia (VAP) caused by
Gram negative multi-resistant (MDR) bacteria. Colimycin often remains the only active
antibiotic. The aim of the study is to demonstrate the superiority of nebulized colimycin
over intravenous colimycin to treat VAP caused by Gramnegative MDR bacteria.